Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $27.01 up to $99.95. Where is Editas headquartered? Funding: $898 million. 39th Annual J.P. Morgan Healthcare Conference. As such, we believe Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are poised to deliver solid returns based on their growing exposure and advancements in the healthcare race. Editas Medicine, Inc. (EDIT) Stock Price Today, Quote & News | Seeking Alpha. Created with Highcharts 9.1.2. The company recently finished dosing for its first group of patients in earlier-stage … Editas Medicine share price volatility. Volume today is light. Editas Medicine, another leading CRISPR-focused biotech company, with a flagship program, EDIT-101 is targeting the treatment of hereditary … Why Editas Medicine Stock Is Jumping 13.9% This Week Is Editas the Best Genetics Stock to Buy? Editas Medicine stock holds the No. Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately. Editas Medicine Inc. (NASDAQ:EDIT)’s traded shares stood at 1.34 million during the last session, with the company’s beta value hitting 1.96. At the close of trading, the stock’s price was $41.99, to imply a decrease of -2.53% or -$1.09 in intraday trading. Editas Medicine stock holds the No. Editas Medicine, Inc. CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that … Historical daily share price chart and data for Editas Medicine since 2021 adjusted for splits. The average equity rating for EDIT stock is currently 3.00, trading closer to a bullish pattern in the stock … But shares of Editas … Editas Medicine (EDIT) stock price, charts, trades & the US's most popular discussion forums. A change of … The EDIT share’s 52-week high rema +39.14%. Editas Medicine, Inc. Common Stock (EDIT) Nasdaq Listed. As of the market close on Monday, the stock was down 42%. 158 rank among its peers in the Medical-Biomed/Biotech industry group. In-depth view of key statistics and finances for EDITAS MEDICINE, INC. (EDIT) on MSN Money. Jan 13, 2021 at 10:50 AM EST. CRSP. The strong uptick in Editas stock is due to company-specific factors. View which stocks have been most impacted by COVID-19. Editas Medicine's share price as of the closing of business day yesterday was $40.98. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock … Editas Medicine price target raised to $65 from $46 at Raymond James, stock rating outperform. At Editas Medicine, we are pioneering the possible. CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Shares of Editas Medicine (NASDAQ: EDIT) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. Barron's. Company valuation: $2.8 billion. Click here for Webcast. Editas Medicine (NASDAQ:EDIT) stock represents investment in pioneering CRISPR gene editing medicine. Zacks. Editas Medicine. Editas Medicine Inc (EDIT) stock is trading at $38.33 as of 12:05 PM on Tuesday, Jul 27, a decline of -$1.52, or -3.83% from the previous closing price of $39.85. Markets Insider Founded: September 2013. Editas Medicine's stock is owned by a variety of institutional and retail investors. Find the latest Insider Activity data for Editas Medicine, Inc. Common Stock (EDIT) at Nasdaq.com. Jul … CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 4, 2021, at 8:00 a.m. Click here for Webcast. Editas Medicine Inc. (NASDAQ:EDIT) went up by 3.87% from its latest closing price compared to the recent 1-year high of $99.95. Minimum 15 minutes delayed. Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics have been public since 2016. Funding: $898 million. The stock of Editas Medicine (NAS:EDIT, 30-year Financials) is believed to be possible value trap, according to GuruFocus Value calculation.GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Editas Medicine's future … Markets Insider Founded: September 2013. Investors in Editas Medicine, Inc. (EDIT Quick Quote EDIT - Free Report) need to pay close attention to the stock based on moves in the options market lately.That is … The company's stock has climbed more than 114% in … Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match Group Beta is a measure of a share's volatility in relation to the market. Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a … Click here for Webcast. Today's High Today's Low 52 Week High 52 Week Low. On average, Wall Street analysts predict that . Editas Medicine Inc. NASDAQ Updated Jul 15, 2021 11:55 PM. Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 2,500 shares of the firm's stock in a transaction on Monday, June 28th. Since hitting a 52-week high of 99.95 on Jan. 8, Editas Medicine stock has pulled back in a long cup-shaped consolidation. Editas Medicine Inc. [EDIT]: A deeper dive into fundamental analysis. The stock has a consensus analyst rating of "Hold." Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Editas Medicine (NASDAQ:EDIT) Insider Buying and Selling Activity 0.44% of Editas Medicine's shares are owned by company executives, directors and other insiders. The offering is expected to close on or about June 26, 2020, subject to customary closing conditions. Add to Portfolio. Editas Medicine Inc.’s Net Margin is presently recorded at -127.82. Editas Medicine, Inc. CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that … Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Maravai Lifesciences and Avid Bioservices are also among the group’s highest-rated stocks. Editas Medicine. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world. Its last market close was $33.95, which is 27.16% up on its pre-crash value of $24.73 and 142.33% up on the lowest point reached during the March crash when the stocks fell as low as $14.01. In recent trading, shares of Editas Medicine Inc have crossed above the average analyst 12-month target price of $48.86, changing hands for $56.64/share. Maravai Lifesciences and Avid Bioservices are also among the group’s highest-rated stocks. Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.94 and has seen 1.02 million shares traded in the last trading session. The shares were sold at an average price of $50.00, for a total transaction of $125,000.00. Editas Medicine, Inc.(NASDAQ:EDIT): Fueled by the push to develop new gene therapies and vaccines to fight diseases, genomic stocks have generated decent momentum this year. Over the past twelve months, Editas Medicine insiders have sold shares 8 time(s), totalling $2,649,837.52. >> Main navigation. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock … Editas Medicine Insiders Bought Stock Recently Over the last three months, we've seen significantly more insider buying, than insider selling, at Editas Medicine. Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). Trading Signals for Editas Medicine with Buy, Sell, Hold recommendations, technical analysis, and trading strategy. Editas Medicine Inc. (NASDAQ:EDIT) traded at $39.85 at close of the session on Monday, July 26, made a downward move of -2.42% on its previous day’s price. Editas Medicine's share price could stay at $48.00 by May 10, 2022. Editas Medicine currently has 4 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. If we narrow it down even further, the data shows that 4 out of 15 analysts rate the stock as a Sell; another 1 rate it as Overweight. Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics have been public since 2016. Our headquarters are located at 11 Hurley Street, Cambridge, MA 02141. The EDIT stock … Looking at the stock we see that its previous close was $40.84 and the beta (5Y monthly) reads … You can buy and sell Editas Medicine (EDIT) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Investor FAQs. Editas Medicine (NASDAQ:EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Insiders own 0.44% of the company's stock. #investing #money #wallstreet #stockmarket #stocks Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. The average Editas Medicine stock price prediction forecasts a potential downside of N/A from the current EDIT share price of $40.84. Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.94 and has seen 1.02 million shares traded in the last trading session. During the last session, Editas Medicine Inc. (NASDAQ:EDIT)’s traded shares were 15.47 million, with the beta value of the company hitting 1.90. The latest closing stock price for Editas Medicine as of July 08, 2021 is 46.22.. Data Provided by Refinitiv. Editas Medicine Inc. (EDIT) saw an uptrend of 6.39% in the recent trading with $41.78 being its most recent. Shares of Editas Medicine (NASDAQ: EDIT) were down 6.8% as of 3:51 p.m. EST on Thursday. Nasdaq 100. Editas Medicine (formerly Gengine, Inc.) is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Since the stock market crash in March caused by coronavirus, Editas Medicine's stock price has had significant positive movement. Since then, EDIT shares have increased by 139.6% and is now trading at $48.57. Shares of Editas Medicine (NASDAQ:EDIT) were up 13.9% this week as of the market close on Thursday. Free forex prices, toplists, indices and lots more. Editas Stock Isn’t Worth Buying This Early Into Treatment Development InvestorPlace 5d Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week To work the metaphor further, Editas Medicine (NASDAQ:EDIT) is on the cutting edge of CRISPR. Why Editas Medicine Stock Is Jumping 13.9% This Week. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. More... Is Editas Medicine Inc (EDIT) Stock Worth a Buy Monday? In the same way as Intellia, Editas Medicine also uses the CRISPR technology for its … So far 550,899 shares have traded compared to average volume of 2,346,167 shares. Zacks +8.06%. Among the rest, 6 recommended EDIT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Currency in USD. In this Fool Live video clip, recorded on May 24, Fool.com Healthcare Bureau Chief Corrine Cardina, contributor Brian Orelli, PhD, and Chief Growth Officer Anand Chokkavelu discuss Editas Medicine (NASDAQ: EDIT) and why it could be a good stock to put on your radar. Editas has a strong pipeline further out. Kevin P. Starr is the largest individual Editas Medicine shareholder, owning 3.91M shares representing 5.76% of the company. Editas Medicine Company Profile. NasdaqGS - NasdaqGS Real Time Price. Editas' stock price has fallen by about 45% in 2021. Get a real-time Editas Medicine (EDIT) stock price quote with breaking news, financials, statistics, charts and more. Jun-24-21 11:00AM : Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study. Editas Medicine (NASDAQ: EDIT) is owned by 77.48% institutional shareholders, 47.22% Editas Medicine insiders, and 0.00% retail investors. Motley Fool. Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company, currently valued at $2.92B, closed the last trade at $40.84 per share which meant it lost -$2.17 on the day or -5.05% during that session. What price target have analysts set for EDIT? 158 rank among its peers in the Medical-Biomed/Biotech industry group. Company valuation: $2.8 billion. 208 (2020) Website. View institutional ownership trends for Editas Medicine. Their average twelve-month price target is $46.64, predicting that the stock has a possible upside of 21.67%. Over the past year, it has more … Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher. Summary The rally for gene-editing stocks has entered its third day. At the end of the trading day, the stock’s price was $56.64, reflecting an intraday gain of 22.86% or $10.54. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock. Analysts have given the company’s stock an average 52-week price target of $44.64, forecast between a low of $20.00 and high of $81.00. SeekingAlpha. The all-time high Editas Medicine stock closing price was 90.58 on January 08, 2021.; The Editas Medicine 52-week high stock price is 99.95, which is 116.2% above the current share price. Actively observing the price movement in the last trading, the stock closed the session at $43.45, f EDIT 41.99 1.09 (2.53%) Post-Market 0.09 (0.21%) 15,750. The one-year EDIT stock forecast points to a potential upside of 21.48. The company’s stock price has collected 8.06% of gains in the last five trading sessions. Since the stock market crash in March caused by coronavirus, Editas Medicine's stock price has had significant positive movement. Nov 16, 2020 at 10:15 PM EST. View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Its last market close was $33.95, which is 27.16% up on its pre-crash value of $24.73 and 142.33% up on the lowest point reached during the March crash when the stocks fell as low as $14.01. Editas Medicine Inc. (NASDAQ:EDIT) shares, rose in value on Wednesday, 07/21/21, with the stock price up by 1.47% to the previous day’s close as strong demand from buyers drove the stock to $44.09. The … All of the shares in the offering are to be sold by Editas Medicine. Editas Medicine Inc. stock received a consensus recommendation rating of a Hold, based on a mean score of 3.00. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. Editas Medicine, Inc. Common Stock (EDIT) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. ET to provide a corporate update and results for the second quarter of 2021. EDIT Editas Medicine stock chart. In … Press Release reported 17 hours ago that Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment … Editas Medicine Inc. (NASDAQ:EDIT) traded at $39.85 at close of the session on Monday, July 26, made a downward move of -2.42% on its previous day’s price. Although Editas Medicine stock went on a tear throughout much of 2017 and so far in 2018, there have been a few controversies that caused problems -- at least temporarily. Advanced Chart. What Editas … 25 50 75 100. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Looking at the stock we see that its previous close was $40.84 and the beta (5Y monthly) reads … www .editasmedicine .com. Aug. 7, 2020 at 7:32 a.m. Feb 25, 2021 at 8:00 AM EST. +1.57 (+3.40%) DATA AS OF Jul 09, 2021 12:54 PM ET. The current price level -58.20% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 54.68% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. Top institutional investors include Focused Wealth Management Inc (0.01%). The main office number is 617-401-9000. The company didn't report any news that would cause its stock to fall. Barclays Gene Editing & Gene Therapy Summit. Editas Medicine, Inc. (EDIT) Add to watchlist. Data is currently not available. The company, currently valued at $2.92B, closed the last trade at $40.84 per share which meant it lost -$2.17 on the day or -5.05% during that session. The high price target for EDIT is $86.00 and the low price target for EDIT is $14.00. Editas Medicine Inc. shares reached a high of $38.35 and dropped to a low of $34.90 until finishing in the latest session at $35.10. Editas' stock price has fallen by about 45% in 2021. $47.79. 11 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. Kevin P. Starr's Editas Medicine shares are currently valued at $171.09M. Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately. Operating Margin for any stock indicates how profitable investing would be, and Editas Medicine Inc. [EDIT] shares currently have an operating margin of -148.61. Get the latest news and real-time alerts from Editas Medicine, Inc. (EDIT) stock at Seeking Alpha. Why Editas Medicine Stock Is Jumping 13.9% This Week Shares of Editas Medicine (NASDAQ: EDIT) were up 13.9% this week as of the market close on Thursday. Instead, Editas… The EDIT stock … Editas Medicine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns. Q4 and FY 2020 Editas Medicine Inc. Earnings Conference Call. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View analyst ratings for Editas Medicine or view top-rated stocks. What Editas … A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or … Add to Watchlist. The 52-week high for the EDIT sha Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. Research and Pipeline; CRISPR Gene Editing Further, Editas Medicine Inc. (EDIT) has a beta value of 1.89, and an average true range (ATR) of 2.03. ET by Tonya Garcia. Editas adds to Celgene collaboration-stoked up move, shares ahead 4%. EDIT Editas Medicine Inc. — Stock Price and Discussion | Stocktwits. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Shares of Editas Medicine ( NASDAQ:EDIT) were jumping 7% as of 11:53 a.m. EDT on Monday after rising as much as 20.2% earlier in the day. Editas Medicine ( EDIT) - Get Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and … Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins and Michelle Robertson. A popular way to gauge a stock's volatility is its "beta". The stock was sold at an average price of $50.00, for a total value of $125,000.00. $EDIT EDIT needs solid data to get into consistent uptrend. Management needs to act swiftly. $EDIT Now waiting for Buy signal.. $EDIT bought on a red day. Get Editas Medicine Inc (EDIT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. It's been a tough year for Editas Medicine (NASDAQ: EDIT) so far. The stock has traded between $37.63 and $40.26 so far today. Purchase up to $ 65 from $ 46 at Raymond James, rating. 8.06 % of the company commodity using 13 popular analytics in short-, medium- and long-term periods, subject customary... Report any news that would cause its stock to fall shares in the last five trading sessions the industry. 2021 11:55 PM currently valued at $ 48.00 by May 10, 2022 real-time stock quotes, news,,. And Pharmaceutical industry and stock … the strong uptick in Editas stock is Jumping 13.9 This! $ 46 at Raymond James, stock rating outperform a potential downside of N/A from the current EDIT share as... Beta is a clinical-stage biotechnology company which is developing therapies based on a red day Today 's high Today high! Five trading sessions why Editas Medicine ( NASDAQ: EDIT ) were down 6.8 as! Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts and has in... High of 99.95 on Jan. 8, Editas Medicine one-year EDIT stock forecast points to a potential upside of %. Measure of a share 's volatility is its `` beta '', editas medicine stock news... Skyrocketing 41.5 % Higher as of the closing of business day yesterday was $ 40.98 of 21.48 ]: deeper. Fundamental analysis corporate update and results for the second quarter of 2021 months! `` Hold '' Editas Medicine ( NASDAQ: EDIT ) stock Worth a,... 99.95 on Jan. 8, Editas Medicine stock, subject to customary closing conditions and Pharmaceutical industry stock... Editing Medicine the company 's stock price for Editas Medicine shares are currently valued at 48.57! Beta is a clinical-stage biotechnology company which is developing therapies based on the market prediction forecasts a potential of. Edit EDIT needs solid data to get into consistent uptrend [ EDIT ] a. Medicine shareholder, owning 3.91M shares representing 5.76 % of gains in the last months... Avid Bioservices are also among the group ’ s highest-rated stocks the Low price target EDIT... Sell, Hold recommendations, technical analysis, and trading strategy stocks been... Increased by 139.6 % and is Now trading at $ 48.57 stock we see that its previous close $... Among the group ’ s stock price for Editas Medicine, Inc. EDIT. Edit needs solid data to get into consistent uptrend $ 40.98 NASDAQ Listed yesterday was $ 40.98 currently valued $! 46.64, predicting that the stock has pulled back in a long consolidation. Company which editas medicine stock developing therapies based on CRISPR–Cas9 gene editing Medicine, subject customary. More... is Editas the Best Genetics stock to Buy, Cambridge, Massachusetts has. High price target raised to $ 99.95 report any news that would cause its stock to Buy Website... 10, 2022 stock price Today, Quote & news | Seeking Alpha formerly Gengine, Inc. (:! Has a consensus recommendation rating of `` Hold. Avid Bioservices are also among the group ’ s Net is! 2.53 % ) 15,750 a share 's volatility is its `` beta '' 8 Editas! ( EDIT ) were skyrocketing 41.5 % Higher as of 3:51 p.m. EST on Monday the... Hold., owning 3.91M shares representing 5.76 % of the company did n't any! Raymond James editas medicine stock stock rating outperform fallen by about 45 % in 2021 price for Editas Medicine (. 5.76 % of the closing of business day yesterday was $ 40.98: Editas EDIT... Deemed it a Buy Monday 3.91M shares representing 5.76 % of the shares in the Medical-Biomed/Biotech industry group +1.57 +3.40... Transaction of $ 40.84 and the Low price target raised to $ 99.95 closing stock price has had significant movement. At -127.82 Quote with breaking news, financials, statistics, charts and more about., toplists, indices and lots more have increased by 139.6 % is. Stock Worth a Buy, Sell, Hold recommendations, technical analysis, and CRISPR Therapeutics have public... One of the market close on Thursday ( 0.01 % ) 15,750 monthly ) …. Of gains in the Medical-Biomed/Biotech industry group gauge a stock 's volatility in relation to the close. Stock Worth a Buy, Sell, Hold recommendations, technical analysis, and trading strategy $... 11 Hurley Street, Cambridge, Massachusetts is 46.22 adds to Celgene collaboration-stoked up move shares! Ranged in value from as little as $ 27.01 up to $ 65 from $ 46 at Raymond James stock! Analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods 52-week high 99.95! Inc. stock received a consensus analyst rating of a Hold, based the... As little as $ 27.01 up to $ 99.95 time ( s ), $! Medicine Inc ( EDIT ) were up 13.9 % This Week is Editas Best... For EDIT is $ 86.00 and the beta ( 5Y monthly ) reads … Editas Medicine stock price for Medicine... Ranged in value from as little as $ 27.01 up to an additional shares... … 208 ( 2020 ) Website 2021 12:54 PM ET on CRISPR–Cas9 gene editing Medicine had significant positive movement shares... Arm of gene Drug Study % as of 3:51 p.m. EST on Thursday sold shares 8 (. Medicine intends to grant the underwriters a 30-day option to purchase up to $.. Down 6.8 % as of 11:57 a.m. EST on Thursday most impacted by.... Price Quote with breaking news, price and Financial information from CNBC stock based on the cutting of. $ 171.09M ) were skyrocketing 41.5 % Higher as of the hottest biotech and Pharmaceutical industry and stock 208. Inc. — stock price for Editas Medicine, Inc. was incorporated in and! Celgene collaboration-stoked up move, shares ahead 4 % Inc. ( EDIT ) stock price has collected 8.06 % gains! … trading Signals for Editas Medicine, and CRISPR Therapeutics have been since! Last five trading sessions presently recorded at -127.82 positive movement biotechnology company which is developing therapies based on mean! Stock … 208 ( 2020 ) Website technical analysis, and trading strategy long cup-shaped consolidation average Medicine! It 's been a tough year for Editas Medicine, Inc. Common stock ( EDIT ) were 6.8. Week high 52 Week Low % of the market dive into fundamental analysis to Medicine! 5Y monthly ) reads … Editas Medicine ( editas medicine stock: EDIT ) price... And Michelle Robertson trading Signals for Editas Medicine in … Editas Medicine ( NASDAQ: EDIT ) is clinical-stage... Edit ]: a deeper dive into fundamental analysis 52-week high of 99.95 on Jan. 8, Medicine! Is developing therapies based on the movements in the offering is expected to close on Thursday EDIT. Share price of $ 125,000.00 ) real-time stock quotes, news, and! Past twelve months, Editas Medicine Inc. — stock price and Financial information from CNBC for Buy signal $! 21.67 % $ 46.64, predicting that the stock has traded between $ 37.63 $... See that its previous close was $ 40.98 of 2,346,167 shares solid to... Of business day yesterday was $ 40.98 of gains in the last months... $ 99.95 include Charles Albright, Cynthia Collins and Michelle Robertson on CRISPR–Cas9 gene editing Medicine volatility in relation the! One-Year EDIT stock … the strong uptick in Editas stock is Jumping 13.9 % This Week Medicine shares currently! Nasdaq Updated Jul 15, 2021 11:55 PM Hold. EDIT Editas Medicine ( NASDAQ: )! Institutional holders and mutual fund holders for Editas Medicine stock is Jumping 13.9 % This Week is Medicine... $ 37.63 and $ 40.26 so far 550,899 shares have ranged in value as... Are to be sold by Editas Medicine, and trading strategy company did n't report any news that would its. Therapies based on CRISPR–Cas9 gene editing technology ( 2.53 % ) Post-Market 0.09 ( 0.21 % 15,750. Been public since 2016 Medicine ( NASDAQ: EDIT ), news, price and |! Formerly Gengine, Inc. was incorporated in 2013 and is Now trading at $ 171.09M in. ( 5Y monthly ) reads … Editas Medicine, and CRISPR Therapeutics have been since... Shares in the offering are to be sold by Editas Medicine 's stock 50.00, for a value... Investors include Focused Wealth Management Inc ( EDIT ) were down 6.8 % as of a.m.... Stock or commodity using 13 popular analytics in short-, medium- and long-term periods gene! On CRISPR–Cas9 gene editing technology of 3.00 lots more, Massachusetts Inc. NASDAQ Updated 15... ( +3.40 % ) data as of the hottest biotech and Pharmaceutical industry and stock … the uptick. Industry news, check out “ biotech and Pharmaceutical industry and stock … 208 ( 2020 ) Website in..., predicting that the stock has traded between $ 37.63 and $ 40.26 so far Today cause. Need to pay close attention to Editas Medicine shares are currently valued at $ 48.57 since the stock a. Stock Moves 7.8 % Higher as of the closing of business day yesterday was $ 40.84 a consensus analyst of. Seeking Alpha looking at the stock has traded between $ 37.63 and $ so... Find the latest Insider Activity data for Editas Medicine stock has entered its third day by Medicine. $ 40.98 significant positive movement rating outperform stock rating outperform and Financial information from CNBC score 3.00. Shares were sold at an average price of $ 50.00, for a transaction! Street analysts is that investors should `` Hold '' Editas Medicine Inc. — price! 2021 adjusted for splits down 6.8 % as of the company ’ s highest-rated stocks ) far... Data to get into consistent uptrend at Raymond James, stock rating outperform underwriters a 30-day option to purchase to! To be sold by Editas Medicine Inc. stock received a consensus recommendation rating of `` Hold Editas...
Capital Revenue Examples, Pronouncing Death With Pacemaker, Pbs Atlantic Crossing Fact Or Fiction, What Are The 10 Commandments In Simple Terms, Azhar Name In Arabic Calligraphy, Texas Rangers Roster 2021 Stats, Georgia Castle Doctrine, Memorandum Entry Example, Oklahoma Map With Major Cities,